India, Aug. 12 -- Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported second-quarter 2026 financial results and corporate updates, highlighting progress with imdusiran for chronic hepatitis B, a strong financial position following its Moderna settlement, and ongoing LNP patent litigation.
Company Profile
Arbutus focuses on developing therapies for infectious diseases, including imdusiran (AB-729) and the oral PD-L1 inhibitor AB-101 for chronic hepatitis B (cHBV). The company also works with Genevant Sciences to protect its lipid nanoparticle (LNP) intellectual property.
Pipeline Update
Imdusiran for Chronic Hepatitis B
Arbutus received FDA Fast Track designation for ...